Davis Polk Advises AstraZeneca on Its Acquisition of Omthera Pharmaceuticals

Davis Polk is advising AstraZeneca PLC in connection with its acquisition of Omthera Pharmaceuticals, Inc. The closing of the transaction, which is subject to the approval of Omthera’s shareholders as well as other customary closing conditions, is expected to occur in the third quarter of 2013. Under the terms of the merger agreement, AstraZeneca will acquire Omthera for up to approximately $443 million, comprised of an upfront payment of approximately $323 million and contractual “contingent value rights” entitling the holders to receive up to $120 million upon the achievement of specified milestones related to Epanova™, Omthera’s investigational product.

More >>

Tags:  Davis Polk & Wardwell LLP | New York

Davis Polk – Fidelity National Financial Acquires Lender Processing Services

Davis Polk is advising Bank of America Merrill Lynch and J.P. Morgan Securities LLC as financial advisers to Fidelity National Financial, Inc. in connection with its $2.9 billion acquisition of Lender Processing Services, Inc. The transaction, which is subject to approval by LPS and FNF stockholders and other customary closing conditions, is expected to close in the fourth quarter of 2013.

More >>

Tags:  Davis Polk & Wardwell LLP | New York

Davis Polk – Aon plc $250 Million Notes Offering

Davis Polk advised Morgan Stanley & Co. LLC and Goldman, Sachs & Co. in connection with an SEC-registered offering by Aon plc of $250 million aggregate principal amount of 4.45% senior notes due 2043. The notes are fully and unconditionally guaranteed by Aon Corporation (an indirect wholly owned subsidiary of Aon plc).

More >>

Tags:  Davis Polk & Wardwell LLP | New York